Association between body mass index reduction and epicardial adipose tissue changes across pharmacological and lifestyle interventions: a multilevel meta-regression analysis.
Obesity-related heart fat shrinks consistently with weight loss across all approaches including newer diabetes drugs, revealing a shared biological mechanism.
This multilevel meta-regression in Cardiovascular Diabetology quantifies the association between BMI reduction and epicardial adipose tissue (EAT) changes across all intervention modalities including GLP-1 receptor agonists, SGLT2 inhibitors, bariatric surgery, and lifestyle interventions, finding consistent EAT reduction proportional to BMI reduction. This supports EAT as a mechanistic link between obesity and cardiovascular risk that responds across treatment modalities including newer pharmacological approaches.
What the study was
- Study design
- meta_regression
- Population
- Adults across intervention studies (pharmacological and lifestyle) with BMI and epicardial adipose tissue measurements
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Cardiovasc Diabetol
Why it surfaced
Directly relevant to cardiometabolic watchlist (GLP-1 RA, SGLT2i); epicardial adipose tissue is an increasingly validated cardiometabolic risk biomarker; Cardiovascular Diabetology is a top-quartile cardiometabolic journal; meta-regression design provides pooled evidence across interventions.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.